ETON Stock Price, Chart, Stats & News
Eton Pharmaceuticals, Inc. (ETON) does not currently pay a dividend.
ETON chart
Fundamentals
Gross margin | 53.46% |
Operating margin | -1.06% |
Pretax margin | -5.70% |
Net margin | -5.75% |
Effective tax rate | -0.94% |
ROA | -4.99% |
ROE | -18.84% |
D/E | 0.35x |
Interest coverage ratio | -0.18x |
ETON valuation
P/E | – |
P/S | 7.93x |
P/B | 23.91x |
P/CF | – |
P/FCF | -1904.18x |
P/OCF | – |
PEG | -4.25x |
EV multiple | 170.05x |
About
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
Similar securities
Based on sector and market capitalization
